1 Min Read
Dec 7 (Reuters) - CymaBay Therapeutics Inc -
* Study is designed to enroll approximately 36 patients in U.S., Canada, Germany and U.K.
* CymaBay Therapeutics announces the initiation of its next phase 2 study of seladelpar (mbx-8025) in patients with primary biliary cholangitis
* Study includes extension phase where patients will be able to continue treatment for 26 weeks
* Primary endpoint will be change in alkaline phosphatase (alp) Source text for Eikon: Further company coverage: